文献速递心力衰竭与心肌病

PIONEER-HF试验:沙库巴曲缬沙坦对比依那普利对急性失代偿性心力衰竭患者心血管生物标志物的影响

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
PubMed 文献 · Eur Heart J · 2019-01-01

PIONEER-HF是一项随机双盲试验,纳入血流动力学稳定后的急性失代偿性心衰住院患者,比较沙库巴曲缬沙坦与依那普利对循环hsTnT、sST2及尿cGMP的影响。结果显示沙库巴曲缬沙坦较依那普利显著降低hsTnT和sST2,并升高尿cGMP,差异在1-4周内显现并持续至8周;第1周hsTnT和sST2与后续心血管死亡或心衰再住院相关。

要点

  • 沙库巴曲缬沙坦较依那普利显著降低急性失代偿性心衰患者的hsTnT和sST2。
  • sST2下降在1周即显现,hsTnT和sST2在4周时降幅分别多16%和9%。
  • 尿cGMP在沙库巴曲缬沙坦组较依那普利组升高,1周时P<0.001。

核心结论

  • 急性失代偿性心衰患者心肌应激生物标志物升高且与结局相关。
  • 沙库巴曲缬沙坦较依那普利减少心肌损伤和血流动力学应激,1-4周内显现。

研究设计与样本

  • PIONEER-HF为随机双盲试验,比较沙库巴曲缬沙坦与依那普利在血流动力学稳定后的急性失代偿性心衰住院患者中的效应。
  • 基线生物标志物完整者共694例,在基线、1、2(sST2、cGMP)、4和8周测量循环hsTnT、sST2和尿cGMP。

主要发现

  • 沙库巴曲缬沙坦较依那普利显著降低hsTnT和sST2,sST2在1周即显现,4周时hsTnT多降低16%(P<0.001)、sST2多降低9%(P=0.0033)。
  • 尿cGMP在沙库巴曲缬沙坦组较依那普利组升高(1周P<0.001)。
  • 各生物标志物组间显著差异持续至8周。
  • 探索性多变量校正分析中,第1周hsTnT和sST2浓度与后续心血管死亡或心衰再住院显著相关。

临床怎么用

  • 在急性失代偿性心衰住院患者血流动力学稳定后,可考虑沙库巴曲缬沙坦以降低心肌应激生物标志物。
  • 第1周hsTnT和sST2水平可能有助于识别后续心血管死亡或心衰再住院高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Circulating high-sensitivity cardiac troponin (hsTn) and soluble ST2 (sST2) reflect myocardial stress in patients with heart failure (HF). Production of cyclic guanosine 3'5' monophosphate (cGMP) in response to activation of natriuretic peptide receptors reduces cardiac afterload and preload. We assessed the effects of sacubitril/valsartan on these biomarkers in patients with reduced ejection fraction and acute decompensated HF (ADHF). METHODS AND RESULTS: PIONEER-HF was a randomized, double-blind trial of sacubitril/valsartan vs. enalapril in hospitalized patients with ADHF following haemodynamic stabilization. We measured circulating hsTnT, sST2, and urinary cGMP at baseline, 1, 2 (sST2, cGMP), 4, and 8 weeks (n = 694 with all baseline biomarkers). Ratios of geometric means (timepoint/baseline) were determined and compared as a ratio for sacubitril/valsartan vs. enalapril. Compared with enalapril, sacubitril/valsartan led to a significantly greater decline in hsTnT and sST2. This effect emerged as early as 1 week for sST2 and was significant for both at 4 weeks with a 16% greater reduction in hsTnT (P < 0.001) and 9% greater reduction in sST2 (P = 0.0033). Serial urinary cGMP increased with sacubitril/valsartan compared with enalapril (P < 0.001, 1 week). The significant differences between treatment groups for each biomarker were sustained at 8 weeks. In an exploratory multivariable-adjusted analysis of cardiovascular death or HF-rehospitalization, the concentrations of hsTnT, sST2 at week 1 were significantly associated with subsequent outcome. CONCLUSION: Biomarkers of myocardial stress are elevated in patients with ADHF and associated with outcome. Compared with enalapril, sacubitril/valsartan reduces myocardial injury and haemodynamic stress as reflected by biomarkers, with an onset that is apparent within 1-4 weeks. CLINICAL TRIALS REGISTRATION: NCT02554890 clinical.trials.gov.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Morrow DA, Velazquez EJ, DeVore AD, et al. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019. PMID: 31093657. doi:10.1093/eurheartj/ehz240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。